Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.

Oyama K, Fushida S, Kaji M, Takeda T, Kinami S, Hirono Y, Yoshimoto K, Yabushita K, Hirosawa H, Takai Y, Nakano T, Kimura H, Yasui T, Tsuneda A, Tsukada T, Kinoshita J, Fujimura T, Ohta T.

J Gastroenterol. 2013 Nov;48(11):1234-41. doi: 10.1007/s00535-012-0746-1. Epub 2013 Jan 22.

PMID:
23338487
[PubMed - indexed for MEDLINE]
2.

Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.

Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.

Intern Med J. 2013 Jan;43(1):73-6. doi: 10.1111/j.1445-5994.2011.02637.x.

PMID:
22141732
[PubMed - indexed for MEDLINE]
3.

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.

Eur J Cancer. 2004 Feb;40(3):403-10.

PMID:
14746859
[PubMed - indexed for MEDLINE]
4.

Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial.

Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Katori H, Horiuchi C, Kimura M, Taguchi T, Yoshida T, Nagao J, Sakuma Y, Toth G.

Int J Clin Oncol. 2009 Aug;14(4):337-43. doi: 10.1007/s10147-008-0874-z. Epub 2009 Aug 25.

PMID:
19705245
[PubMed - indexed for MEDLINE]
5.

Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.

Hamada S, Hinotsu S, Kawai K, Yamada S, Narita S, Kamba T, Nishiyama H, Arai Y, Habuchi T, Ogawa O, Kawakami K.

Support Care Cancer. 2014 Aug;22(8):2161-6. doi: 10.1007/s00520-014-2182-7. Epub 2014 Mar 21.

PMID:
24652048
[PubMed - indexed for MEDLINE]
7.

Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R, Gori B, Altavilla A, D'Antoni I, Del Signore E, Stumbo L, De Luca C, Cimadon B, Cortesi E, Gamucci T, Di Seri M.

Support Care Cancer. 2011 Aug;19(8):1159-64. doi: 10.1007/s00520-010-0930-x. Epub 2010 Jun 16.

PMID:
20552375
[PubMed - indexed for MEDLINE]
8.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group.

Cancer. 2003 Jun 15;97(12):3090-8.

PMID:
12784346
[PubMed - indexed for MEDLINE]
Free Article
9.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
[PubMed - indexed for MEDLINE]
10.

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.

Hu Z, Cheng Y, Zhang H, Zhou C, Han B, Zhang Y, Huang C, Chang J, Song X, Liang J, Liang H, Bai C, Yu S, Chen J, Wang J, Pan H, Chitkara DK, Hille DA, Zhang L.

Support Care Cancer. 2014 Apr;22(4):979-87. doi: 10.1007/s00520-013-2043-9. Epub 2013 Nov 26.

PMID:
24276953
[PubMed - indexed for MEDLINE]
11.

Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.

Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM.

Support Care Cancer. 2009 Aug;17(8):1065-70. doi: 10.1007/s00520-008-0545-7. Epub 2008 Dec 6.

PMID:
19066985
[PubMed - indexed for MEDLINE]
12.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F.

J Clin Oncol. 2005 Apr 20;23(12):2822-30. Erratum in: J Clin Oncol. 2005 Aug 20;23(24):5851. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
15837996
[PubMed - indexed for MEDLINE]
Free Article
13.

The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.

Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H.

Support Care Cancer. 2013 Sep;21(9):2575-81. doi: 10.1007/s00520-013-1835-2. Epub 2013 May 5.

PMID:
23644992
[PubMed - indexed for MEDLINE]
14.

Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.

Choi CH, Kim MK, Park JY, Yoon A, Kim HJ, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS.

Support Care Cancer. 2014 May;22(5):1181-7. doi: 10.1007/s00520-013-2070-6. Epub 2013 Dec 12.

PMID:
24337621
[PubMed - indexed for MEDLINE]
15.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ.

Support Care Cancer. 2010 Apr;18(4):423-31. doi: 10.1007/s00520-009-0680-9. Epub 2009 Jul 1.

PMID:
19568773
[PubMed - indexed for MEDLINE]
16.

Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.

Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM.

Eur J Cancer. 2003 Jul;39(10):1395-401.

PMID:
12826042
[PubMed - indexed for MEDLINE]
17.

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.

Eur J Cancer. 2005 Jun;41(9):1278-85.

PMID:
15939263
[PubMed - indexed for MEDLINE]
18.

Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.

Uchida M, Ikesue H, Kato K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Egashira N, Akashi K, Oishi R.

Am J Health Syst Pharm. 2013 Feb 15;70(4):343-9. doi: 10.2146/ajhp120363.

PMID:
23370141
[PubMed - indexed for MEDLINE]
19.

Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.

Hu W, Fang J, Nie J, Dai L, Chen X, Zhang J, Ma X, Tian G, Han J.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1129-36. doi: 10.1007/s00280-014-2446-4. Epub 2014 Apr 21.

PMID:
24748417
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk